Risperdal Lawsuit Information

Risperdal, a medication prescribed for schizophrenia and bipolar disorder, has been at the center of a large-scale legal battle. Manufactured by Johnson & Johnson's Janssen division, Risperdal has faced numerous lawsuits due to its side effects and illegal marketing practices. These lawsuits allege that the drug was marketed for unapproved uses, including to children and elderly patients with dementia, despite known risks. Johnson & Johnson has already paid billions in settlements and fines, including a $2.2 billion settlement for criminal and civil charges relating to illegal marketing. As litigation continues to unfold, many affected individuals are coming forward to seek justice and compensation for the harm they have suffered.

One of the most concerning side effects of Risperdal is gynecomastia, an abnormal development of breast tissue in males. This condition has been reported to be permanent and can only be treated with surgeries like breast reduction or mastectomy. In addition to gynecomastia, patients, particularly the elderly with dementia and children, have suffered from other severe side effects. These include an increased risk of death, rapid weight gain, elevated cholesterol levels, and various behavioral changes. These side effects have significantly impacted the lives of many individuals, leading to both physical and emotional distress.

If you or a loved one has been affected by Risperdal, it's crucial to understand that you have the right to seek compensation. Filing a claim as part of the ongoing mass tort against Johnson & Johnson can help you receive the justice and financial support you deserve for your suffering. Our legal team is dedicated to supporting those impacted by Risperdal's adverse effects. We encourage you to contact us to discuss your case, understand your legal options, and join the many others who are holding Johnson & Johnson accountable for their actions. Your story matters, and together, we can fight for the compensation you are rightfully owed.